Abstract
Genomic profiling and PD-L1 expression of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CIBI308ALTER-C201 trial (035)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
